Img header logo

ESG Data

アンカーリンク用

Regarding the data for FY2020 marked with , we have received independent assurance in our Sustainability data 2021 (PDF version) so as to bolster the reliability of the information. For details, please see the “Independent Practitioner's Assurance.”Governance Data

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Governance Data

Corporate Governance
Item Scope Unit FY2016 FY2017 FY2018 FY2019 FY2020
Board structure Directors (Total) Non-consolidated Persons 7 7 8 8 8
Independent outside directors Non-consolidated Persons 2 2 3 3 3
Female directors Non-consolidated Persons 0 0 0 0 1
Board of Auditors structure Auditors (Total) Non-consolidated Persons 4 4 4 4 4
Independent outside auditors Non-consolidated Persons 2 2 2 2 2
Female auditors Non-consolidated Persons 1 1 1 1 1
Director Remuneration Total Non-consolidated Million yen 345 336 360 368 384
President, Representative Director, and Chief Executive Officer Non-consolidated Million yen - - 114 116 126
Auditor Remuneration Total Non-consolidated Million yen 71 76 77 78 83
Number of Board of Directors meetings Non-consolidated Times 15 13 13 13 13
Number of Board of Auditors meetings Non-consolidated Times 13 13 14 14 19
Board attendance rate(directors) Non-consolidated % - 100 100 100 98.6
Board attendance rate(auditors) Non-consolidated % - - 100 92.3*1 100
  • The attendance rate of Audit & Supervisory Board Members excluding the Audit & Supervisory Board Member who resigned due to illness on March 27, 2020 was 100%.
Compliance
Item Scope Unit FY2016 FY2017 FY2018 FY2019 FY2020
Compliance training attendance rate Non-consolidated % - - 100 100 100
Number of reports Discrimination and harassment related Non-consolidated Incidents - - - 22 15
Personnel and labor management related Non-consolidated Incidents - - - 2 1
Others Non-consolidated Incidents - - - 44 6
Total Non-consolidated Incidents - - 44 68 22
Number of compliance violations*2 Discrimination and harassment related Non-consolidated Incidents - - - 3 1
Personnel and labor management related Non-consolidated Incidents - - - 0 0
Bribery cases Non-consolidated Incidents 0 0 0 0 0
Others Non-consolidated Incidents - - - 6 0
Total Non-consolidated Incidents - - 5 9 1
Costs for legal violations Non-consolidated Million yen - - - - 0
Number of facilitation payments Non-consolidated Incidents 0 0 0 0 0
  • Those judged to be disciplinary
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Data

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Environmental Data

GHG emissionsThe scope of environmental data is non-consolidated basis.
Since the figures in the table are rounded, the breakdown totals may not always coincide with the overall totals.
Item Scope Unit FY2016 FY2017 FY2018 FY2019 FY2020
GHG emissions (Market-basis) Production and research sites kt-CO2 27.3 27.2 26.1 25.2 24.1
Headquarters and other Sites in Japan(including tenant locations) kt-CO2 2.6 2.6 2.4 2.1 2.0
Total kt-CO2 29.9 29.8 28.5 27.3 26.1
GHG emissions scope breakdown (Market-basis) Scope 1 (Breakdown by GHG type) Energy-derived CO2 All operation sites kt-CO2 8.5 8.5 9.0 9.7 10.0
Hydrofluorocarbon (HFC) - 0.2 0.5 0.4 0.1
Total 8.5 8.7 9.5 10.1 10.1
Scope 2 All operation sites kt-CO2 21.4 21.1 19.1 17.1 15.9
  • Sites where data were collected: Fujiyama Plant, Joto Pharmaceutical Product Development Center, Yamaguchi Plant (added from FY2018), Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc.
  • GHG emissions are calculated using the following formula.
    GHG emissions = Purchased electricity × Adjusted emission factor published by electric power company + Σ (Fuel consumption × Unit calorific value × Carbon emission factor × 44/12) + Σ (Fluorocarbon leakage amount × Global warming potential)
  • The amount of green electric power certified under the Green Energy Certificate and renewable energy certified under J-Credit Scheme are deducted.
  • GHG types: Based on the Greenhouse Gas Emissions Accounting, Reporting, and Disclosure System of the Act on Promotion of Global Warming Countermeasures
GHG emissions in the value chain (Scope3)
Category Calculation method Notes Scope Unit FY2016 FY2017 FY2018 FY2019 FY2020
Cat1 Purchased goods and services GHG emissions (scope  1,2) volume of our major suppliers of raw materials and materials (accounting for 80% or more of our raw materials or materials purchase costs) multiplied by the ratio of the sales to ONO out of the total sales of the supplier. Ratios for other business suppliers are assumed to follow the same trend as for major suppliers, and are calculated using the ratio of GHG emissions to the transaction amount at major suppliers. ·This category is closely associated with our business activities since active pharmaceutical ingredients for manufacturing of drugs, intermediate products and research reagents are included.
·Covers production and research sites
·Figures for FY2020 are not calculated because our major suppliers had not published their CSR reports at the time of calculation.
All operation sites kt-CO2 97.1 8.5 8.1 11.5 -
Cat2 Capital goods Amount of capital investment, multiplied by emission factor Calculated based on capital goods treated as fixed assets. The fixed assets used in this calculation are essential for business activities. kt-CO2 27.0 52.6 60.4 26.9 25.8
Cat3 Fuel- and energy-related activities not included in scope 1 or scope 2 Amount of non-renewable electricity purchased, multiplied by emission factor - kt-CO2 1.5 1.5 1.5 2.8 2.7
Cat4 Upstream transportation and distribution Transport data on deliveries from our production sites and distribution centers to destinations, multiplied by emission factor - kt-CO2 0.1 0.1 0.1 0.1 0.1
Cat5 Waste generated in operations Weight of each type of industrial waste generated, multiplied by emission factor - kt-CO2 0.3 0.3 0.3 0.3 0.3
Cat6 Business travel Business travel costs, multiplied by emission factor Covers travels by airplane or Shinkansen bullet train kt-CO2 2.2 2.5 2.3 4.0 0.4
Cat7 Employee commuting Commuting costs, multiplied by emission factor - kt-CO2 0.3 0.4 0.4 0.5 0.4
Cat8 Upstream leased assets Cost of gasoline for leased company cars, multiplied by emission factor - kt-CO2 3.5 3.5 3.3 2.9 2.0
Cat9 Downstream transportation and distribution GHG emissions stated in CSR reports on our major pharmaceutical wholesalers, multiplied by percentage of our net sales included in all net sales of major pharmaceutical wholesalers ·Transportation and distribution are important business activities to control distribution of and to ensure stable supply of drugs.
· Figures for FY2020 are not calculated because our major pharmaceutical wholesalers had not published their CSR reports at the time of calculation.
kt-CO2 6.2 5.3 5.3 4.9 -
Cat10 Processing of sold products - We make only finished products kt-CO2 Not relevant Not relevant Not relevant Not relevant Not relevant
Cat11 Use of sold products - No energy is consumed during the use of ONO products Not relevant Not relevant Not relevant Not relevant Not relevant
Cat12 End-of-life treatment of sold products Weight of each type of our product container or packaging disposed of as waste, multiplied by emission factor - kt-CO2 0.2 0.1 0.2 0.2 0.2
Cat13 Downstream leased assets Floor space of asset (building) owned and rented out categorized by use, multiplied by emission factor - kt-CO2 0.3 0.3 0.3 0.3 0.3
Cat14 Franchises - ONO does not operate franchises kt-CO2 Not relevant Not relevant Not relevant Not relevant Not relevant
Cat15 Investments - There is no investment involving large amounts of greenhouse gas emissions. kt-CO2 Not relevant Not relevant Not relevant Not relevant Not relevant
Total kt-CO2 138.7 75.1 82.2 54.4 -
  • Categories 1 and 9 of scope 3 and their total for FY2020 are not calculated because our major suppliers and pharmaceutical wholesalers had not published their CSR reports at the time of calculation.
  • The emissions factors are from the “Emission Factor Database on Accounting for Greenhouse Gas Emissions throughout the Supply Chain (ver. 2.4 in FY2016 and FY2017, ver. 2.6 in FY2018, ver. 3.0 in FY2019, and ver. 3.1 in FY2020),” published by the Ministry of the Environment of Japan.
Energy consumption
Item Scope Unit FY2016 FY2017 FY2018 FY2019 FY2020
Energy consumption Production and research sites MWh 84,173.4 83,906.2 88,423.4 96,369.2 98,025.2
Headquarters and other Japan offices/sites(including tenant locations) MWh 5,150.1 5,256.9 5,340.4 5,236.4 5,179.1
Total MWh 89,323.5 89,163.1 93,763.8 101,605.6 103,204.3
Share of renewable energy in total electricity consumption Electricity consumption Private power generation (renewable) (solar power generation) All operation sites MWh 54.0 55.3 65.0 63.0 63.3
Purchased electricity (renewable) (hydroelectric power generation) MWh - - - 1,278.0 1,954.7
Private power generation (non-renewable) MWh 7,967.9 7,927.0 8,856.2 8,185.3 8,566.3
Purchased electricity (non-renewable) MWh 41,770.2 41,820.1 43,734.4 46,351.7 45,232.2
Total (total electricity consumption) MWh 49,792.1 49,802.4 52,655.5 55,878.0 55,816.5
Amount of credits purchased Solar power generation MWh - - - 2,427.0 4,946.6
Biomass power generation MWh - - 2,900.0 2,460.9 386.2
Renewable energy usage*6 MWh 54.0 55.3 2,965.0 6,228.9 7,350.7
Renewable energy usage rate (renewable energy usage / total electricity consumption) 0.1 0.1 5.6 11.1 13.2
  • Sites where data were collected: Fujiyama Plant, Joto Pharmaceutical Product Development Center, Yamaguchi Plant (added from FY2018), Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc.
  • Renewable energy usage = Private power generation (renewable) + Purchased electricity (renewable) + Amount of credits purchased
Water intake and wastewater volume by site (unit: 1,000 m3)
Site name River in the area Wastewater drainage destination FY2016 FY2017 FY2018 FY2019 FY2020
Water intake volume Wastewater volume Water intake volume Wastewater volume Water intake volume Wastewater volume Water intake volume Wastewater volume Water intake volume Wastewater volume
Fujiyama Plant Fuji River River 195.7 128.9 205.6 148.6 240.2 178.4 185.0 145.1 157.8 125.0
Joto Pharmaceutical Product Development Center Yodo River Sewer 7.2 7.2 5.5 5.5 6.0 6.0 5.1 5.1 4.6 4.6
Yamaguchi Plant Fushino River River - - - - 8.2 8.2 18.1 18.1 18.6 17.7
Minase Research Institute Yodo River Sewer 45.2 45.2 51.3 51.3 41.2 41.2 39.1 39.1 33.7 33.7
Fukui Research Institute Kuzuryu River Sewer 39.4 7.5 38.7 5.2 31.3 5.0 27.3 5.7 13.7 2.6
Tsukuba Research Institute Lake Kasumigaura Sewer 10.9 10.9 8.1 8.1 6.0 6.0 7.1 7.1 7.2 7.2
Head Office and other sites in Japan (including tenant locations) Rivers/lake in the areas where major business sites are located*7 Sewer - - 15.9 15.9 15.1 15.1 15.0 15.0 10.0 10.0
total 298.4 199.7 325.1 234.6 348.0 259.9 296.7 235.2 245.6 200.8
  • Sites where data were collected: Fujiyama Plant, Joto Pharmaceutical Product Development Center, Yamaguchi Plant (added from FY2018), Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc.
  • Basins of major offices: Toyohira River, Okura River, Arakawa River, Sakawa River, Kiso River, Lake Biwa, Yodo River, Ota River, Yoshino River, Naka River
Activities to reduce water consumption (rate of recycled water)
Item Scope Unit FY2016 FY2017 FY2018 FY2019 FY2020
Percentage of reused water Production and research sites % - 5.9 4.8 5.5 2.0
Waste Management, and Recycling Containers and Product Packaging
Item Scope Unit FY2016 FY2017 FY2018 FY2019 FY2020
Industrial waste Waste generated Production and research sites t 534.6 719.1 446.4 430.8 502.7
Special management industrial waste (hazardous waste)*8 Production and research sites t 138.1 137.0 145.6 161.9 171.2
final landfill disposal Production and research sites t 0.7 7.4 0.4 0.2 1.1
final landfill disposal rate Production and research sites % 0.1 1.0 0.1 0.1 0.2
final landfill disposal (Non-industrial waste is included) Production and research sites t 10.7 18.0 9.4 6.7 5.9
Container and packaging usage Plastic Production t - 164.7 171.7 162.8 161.5
Paper Production t - 192.0 202.7 200.9 198.1
Glass (colorless) Production t - 0.0 0.0 0.0 0.0
Glass (brown) Production t - 0.3 0.3 0.3 0.2
Obligatory recycling amount Plastic Production t - 34.7 35.5 31.2 35.1
Paper Production t - 1.6 1.6 1.5 1.4
Glass (colorless) Production t - 0.0 0.0 0.0 0.0
Glass (brown) Production t - 0.0 0.0 0.0 0.0
Commissioning fee paid for recycling Production 1,000 yen - 1,723.0 1,650.0 1,546.0 1,814.0
  • Sites where data were collected: Fujiyama Plant, Joto Pharmaceutical Product Development Center, Yamaguchi Plant (added from FY2018), Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute
  • Of FY2017 final industrial landfill disposal volume in, the amount of waste (5.8 tons) from renovation of Joto Pharmaceutical Product Development Center was included.
  • Special management industrial waste (hazardous waste) is defined under the Waste Management and Public Cleansing Law as waste that has properties of explosiveness, toxicity, infectiousness, and/or possibly causing damage to human health or the living environment. We strive to manage this type of waste properly.
Prevention of Air Pollution and Water Pollution
Item Scope Unit FY2016 FY2017 FY2018 FY2019 FY2020
Emissions into the air SOx Production and research sites t 0.0 0.0 0.0 0.0 0.0
NOx Production and research sites t 13.8 7.8 8.4 8.1 8.1
Particulate matter Production and research sites t 0.4 0.3 0.3 0.3 0.3
PRTR substance Production and research sites t 0.2 0.2 0.2 0.1 0.4
Emissions into water Wastewater Production and research sites 1,000m3 199.7 218.7 244.8 220.2 190.8
BOD Production and research sites t 2.4 2.2 1.3 1.3 1.2
PRTR substance Production and research sites t 0.0 0.0 0.0 0.0 0.0
Management of Chemicals (PRTR substances)
Item Scope Unit FY2016 FY2017 FY2018 FY2019 FY2020
Amount handled by the notified facilities Acetonitrile Production and research sites t 8.3 9.0 7.2 8.5 10.4
Normal-hexane Production and research sites t 3.0 3.0 2.8 3.0 2.6
Total Production and research sites t 11.2 12.0 10.0 11.5 13.0
Dioxins Production and research sites mg-TEQ - - - - -
Notified release(into the air) Acetonitrile Production and research sites t 0.2 0.4 0.2 0.1 0.3
Normal-hexane Production and research sites t 0.0 0.0 0.0 0.0 0.0
Total Production and research sites t 0.2 0.4 0.2 0.1 0.3
Dioxins Production and research sites mg-TEQ 0.3 - - - -
Notified release(into public waters) Acetonitrile Production and research sites t 0.0 0.0 0.0 0.0 0.0
Normal-hexane Production and research sites t 0.0 0.0 0.0 0.0 0.0
Total Production and research sites t 0.0 0.0 0.0 0.0 0.0
Dioxins Production and research sites mg-TEQ 0.0 - - - -
Notified transfer(contained in waste) Acetonitrile Production and research sites t 8.1 8.8 6.9 8.4 10.1
Normal-hexane Production and research sites t 2.9 3.0 2.8 3.0 2.6
Total Production and research sites t 10.9 11.8 9.8 11.3 12.7
Dioxins Production and research sites mg-TEQ 16.8 0.0 - - -
Notified transfer(Into public sewage) Acetonitrile Production and research sites t 0.0 0.0 0.0 0.0 0.0
Normal-hexane Production and research sites t 0.0 0.0 0.0 0.0 0.0
Total Production and research sites t 0.0 0.0 0.0 0.0 0.0
Dioxins Production and research sites mg-TEQ 0.0 - - - -
Notified release and transfer (total) Acetonitrile Production and research sites t 8.3 9.0 7.2 8.5 10.4
Normal-hexane Production and research sites t 3.0 3.0 2.8 3.0 2.6
Total Production and research sites t 11.2 12.0 10.0 11.5 13.0
Dioxins Production and research sites mg-TEQ 17.0 - - - -
Management of Chemicals (PCB)
Item Scope Unit FY2016 FY2017 FY2018 FY2019 FY2020
Joto Pharmaceutical Product Development Center Stored(Fluorescent lamp) Production and research sites Stand 552 552 552 0 0
Disposed Production and research sites Stand 6 6 6 558 559
Minase Research Institute Disposed Production and research sites Stand 2 2 2 2 2
  • Joto Pharmaceutical Product Development Center in FY2007, FY2019 and in FY2020 and Minase Research Institute in FY2014 delivered PCBs to the Japan Environmental Storage & Safety Corporation, a PCB waste treatment service provider. A condenser was identified by reinspection of Joto Pharmaceutical Product Development Center in FY2020, which was disposed of in that fiscal year.
Environmental Management
Item Scope Unit FY2016 FY2017 FY2018 FY2019 FY2020
Status of acquisition of ISO 14001 certification for sites Production site 100% 100% 100% 100% 100%
  • Scope of ISO 14001 certification at production sites (Including those under construction for ISO14001). Certification is scheduled during FY 2021 in Yamaguchi Plant.
Environmental Violations
Item Scope Unit FY2016 FY2017 FY2018 FY2019 FY2020
Number of breaches of legal obligation/regulatory violations All operation sites Cases 0 0 0 0 0
Amount of breach-/violation-related fines All operation sites Million yen 0 0 0 0 0
Environmental liabilities as of fiscal year-end All operation sites Million yen 0 0 0 0 0
  • Breach/violation cases with fines of USD 10,000 or more
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Contribution Activities Data

Initiatives for medical advancement
Item Scope Unit FY2016 FY2017 FY2018 FY2019 FY2020
Osamu Hayaishi Memorial Award - Persons - 1 1 1 1
Recipients of theresearch grant - Persons 12 12 12 12 12
Recipients of theresearch scholarship grant(40 years old and below) - Persons 16 16 16 16 16
Recipients of the Osamu Hayaishi Memorial Scholarship for Study Abroad - Persons 8 8 8 8 8
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system